Biomark Diagnostics Inc Stock Price, News & Analysis

BioMark Diagnostics (OTCQB: BMKDF) announced support for the 2026–2035 Pan-Canadian Lung Cancer Action Plan, aligning its next‑generation metabolomics and AI liquid biopsy approach with the plan's goal to reduce lung cancer mortality by 30% over the next decade. The company highlighted clinical results showing AI‑enabled biomarker testing can identify more early‑stage cancers, including in non‑smokers, and said its blood‑based tests can complement low‑dose CT screening and help expand access in underserved and remote communities.

BioMark invited partnerships with national and provincial healthcare providers and community organizations to scale early detection across Canada.

BioMark (OTCQB: BMKDF) was selected as the core diagnostic partner for Germany's HANSE lung cancer screening trial, a 10,000‑participant study that began in October 2025. The consortium will integrate metabolomic profiling, radiomics, and clinical data into a risk model to improve early lung cancer detection and nodule classification for adults aged 55–79. The initiative is supported by the EUREKA Network and involves multiple German clinical centers. BioMark cites a recent capital raise that enabled scaling of its Quebec City laboratory, which is progressing toward full certification to handle the trial's sample logistics. Successful execution is expected to provide clinical evidence for regulatory submissions and European commercialization.

BioMark Diagnostics (OTCQB: BMKDF) has secured crucial patents in China and Japan for its metabolic liquid biopsy platform designed for early lung cancer detection. The company's technology has demonstrated over 90% sensitivity for early-stage lung cancer detection in a recent study published in the International Journal of Molecular Sciences.

The granted patents (Chinese patent N° ZL 201980092723.X and Japanese patent N° 2023-111262) strengthen BioMark's position in Asia's largest healthcare markets, where the liquid biopsy market is projected to reach US$670 million in China and US$912 million in Japan by 2030.

BioMark Diagnostics (OTCQB: BMKDF) has entered a strategic Expression of Interest agreement with SAMA CONSULTING SARL to implement its liquid biopsy platform for lung cancer detection in Tunisia. The partnership aims to address the critical healthcare need in North Africa, where lung cancer is a leading cause of cancer-related deaths.

The collaboration will begin with a proof-of-concept trial in October 2025, evaluating the platform's performance within Tunisia's healthcare system. Following successful implementation, BioMark plans to expand across North Africa, potentially reaching a market of over 90 million people across Tunisia, Algeria, Morocco, and seven additional countries.

BioMark Diagnostics (OTCQB: BMKDF), a liquid biopsy test developer, has completed a strategic laboratory equipment leasing agreement that doubles its testing capacity in Quebec. This expansion supports the upcoming commercial launch of its metabolomic-based lung cancer diagnostic assay and enhances the company's ability to provide advanced diagnostic analytical molecular services.

The upgraded facility will serve as a certified and accredited laboratory, enabling broad deployment through clinical partnerships, centralized testing services, and expanded contract research programs. The expansion positions BioMark to meet increasing global demand for non-invasive liquid biopsy diagnostics and supports research collaborations with healthcare institutions and pharmaceutical companies.

BioMark Diagnostics (OTCQB:BMKDF), a liquid biopsy test developer for early cancer detection, has reported significant achievements for fiscal year 2025 and outlined strategic goals for 2025-2026. The company successfully raised CAD $4.26 million through private placement and secured CAD $365,000 in non-dilutive grants.

Key operational highlights include advancing AI-powered diagnostic assays for multiple cancers, initiating ISO 15189:2022 certification, and preparing for CLIA certification. The company achieved an 18% reduction in liabilities while tripling current assets. BioMark has strengthened partnerships with AstraZeneca, University of Maryland, and Ohio State University.

Looking ahead, BioMark plans to double laboratory capacity in Q2 2025, complete a 6,000-patient lung cancer clinical trial in Q3 2025, launch commercial operations in Quebec, and begin U.S. diagnostic service rollout in early 2026.

BioMark Diagnostics (BMKDF) has announced a breakthrough publication showcasing their novel Graph Neural Network (M-GNN) model for early lung cancer detection. The research, published in the International Journal of Molecular Sciences, demonstrates how the company's AI-powered approach enhances cancer diagnosis by analyzing metabolomics data alongside patient demographics and metabolic pathway information.

The study represents a collaboration between BioMark's scientific team, Harrisburg University of Science and Technology, and St. Boniface Hospital Research Centre. The M-GNN framework leverages advanced AI to interpret complex biological interactions, offering a scalable and interpretable tool for precision oncology that could be applied to BioMark's existing assays for lung, breast, and neuroendocrine cancers.

BioMark Diagnostics (BMKDF) has published a landmark study validating its liquid biopsy test for early-stage lung cancer detection in the International Journal of Molecular Sciences. The study analyzed 680 plasma samples in a discovery cohort and 216 samples for validation, demonstrating the test's ability to distinguish early-stage non-small cell lung cancer (NSCLC) from non-cancerous lung conditions.

The research achieved remarkable results with Area Under the ROC Curve (AUROC) values exceeding 93% for detecting stage I-II NSCLC. The study's control group notably included patients with various non-cancerous lung diseases, strengthening the validation of the test's specificity. This blood-based test offers advantages over current screening methods like low dose computed tomography (LDCT), which can produce false positives leading to unnecessary procedures.

BioMark Diagnostics (CSE: BUX) (OTCQB: BMKDF) has announced its uplisting from the OTC Pink Open Market to the OTCQB Venture Market effective May 8th, 2025. The company, which develops liquid biopsy tests for early cancer detection, will maintain its DTC eligibility for electronic clearing and settlement in the United States. The stock will continue trading on the Canadian Securities Exchange under "BUX" with no action required from current shareholders.

CEO Rashid Bux highlighted this uplisting as a strategic move to increase visibility among U.S. investors and enhance stock liquidity. The timing aligns with BioMark's plans to commercially launch its liquid biopsy test for lung cancer and expand operations in the U.S. through potential collaborations with comprehensive cancer screening centers.